Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

574 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van 't Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM. van Schaik RH, et al. Pharmacogenomics. 2011 Aug;12(8):1137-46. doi: 10.2217/pgs.11.54. Epub 2011 Aug 10. Pharmacogenomics. 2011. PMID: 21830868
Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?
Heijmen L, Verstappen MC, Ter Voert EE, Punt CJ, Oyen WJ, de Geus-Oei LF, Hermans JJ, Heerschap A, van Laarhoven HW. Heijmen L, et al. Among authors: van laarhoven hw. Crit Rev Oncol Hematol. 2012 Aug;83(2):194-207. doi: 10.1016/j.critrevonc.2011.12.008. Epub 2012 Jan 23. Crit Rev Oncol Hematol. 2012. PMID: 22269446 Review.
Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S, Cats A, Meijer SL, van Laarhoven HW. Kordes S, et al. Among authors: van laarhoven hw. Crit Rev Oncol Hematol. 2014 Apr;90(1):68-76. doi: 10.1016/j.critrevonc.2013.10.004. Epub 2013 Oct 12. Crit Rev Oncol Hematol. 2014. PMID: 24183912 Review.
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven HW, Vriens B, Wasser MN, van Leeuwen-Stok AE, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG). Charehbili A, et al. Among authors: van laarhoven hw, van warmerdam lj, van de ven s, van de velde cj, van leeuwen stok ae. Ann Oncol. 2014 May;25(5):998-1004. doi: 10.1093/annonc/mdu102. Epub 2014 Feb 27. Ann Oncol. 2014. PMID: 24585721 Free article. Clinical Trial.
574 results